This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Revotar Biopharmaceuticals AG
Drug Names(s): bimosiamose microemulsion, TBC1269
Description: Bimosiamose, an inhibitor of interactions between the selectin adhesion receptors and their ligands, is in clinical trials for asthma and psoriasis. Bimosiamose bocks interaction between all selectins (L, P and E) and their ligands.
Deal Structure: Encysive formed Revotar in 2000 to conduct research and development of novel small molecule compounds and to develop and commercialize selectin antagonists, including bimosiamose.
In April 2005, the stockholders of Revotar agreed to restructure Revotars capitalization. Revotars stockholders other than the Company contributed additional funds to Revotar, and the Companys ownership was reduced to approximately 14% of the outstanding common stock of Revotar. Revotars other stockholders subsequently purchased the remaining shares of Revotar common stock owned by the Company for nominal consideration. The Company no longer has an ownership interest in Revotar. Upon the funding of Revotar by the other stockholders, the Company licensed its worldwide rights to bimosiamose and certain follow-on compounds to Revotar for which it could receive future royalty payments from Revotar in the event that these compounds are subsequently approved and commercialized, or licensed to a third...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: